Related Experiment Video
Updated: Mar 23, 2026

Line Shape Analysis of Dynamic NMR Spectra for Characterizing Coordination Sphere Rearrangements at a Chiral Rhenium Polyhydride Complex
Published on: July 27, 2022
Destructive interactions of dirhodium(II) tetraacetate with β metallothionein rh1a
Daisy L Wong1, Martin J Stillman1
1Department of Chemistry, The University of Western Ontario, London, ON N6A 5B7, Canada. stillman@uwo.ca.
Abstract:
Metal-based therapeutics are vital tools in medicine. Metal-chelating proteins can dramatically decrease drug efficacy. Dirhodium(II) tetraacetate, a potential anticancer compound, binds in vitro to 8 cysteines of the human metallothionein 1a β-fragment. Electrospray ionization mass spectrometry shows that the final product is the Rh2(4+) core encapsulated by the β fragment of the metallothionein protein protein.
Insights
Dirhodium(II) tetraacetate, an anticancer drug candidate, binds to metallothionein proteins. This interaction encapsulates the drug core within the protein fragment, impacting metal-based therapeutic efficacy.
Area of Science:
- Biochemistry
- Medicinal Chemistry
- Materials Science
Background:
- Metal-based therapeutics are crucial in medical treatments.
- Metal-chelating proteins can interfere with the efficacy of metal-based drugs.
- Understanding these interactions is key to developing effective metal-based therapies.
Purpose of the Study:
- To investigate the binding interaction between dirhodium(II) tetraacetate and human metallothionein 1a β-fragment.
- To characterize the resulting complex formed by this interaction.
Main Methods:
- In vitro binding assays to assess the interaction between dirhodium(II) tetraacetate and the metallothionein 1a β-fragment.
- Electrospray ionization mass spectrometry (ESI-MS) to analyze the structure and composition of the resulting complex.
Main Results:
- Dirhodium(II) tetraacetate was found to bind to eight cysteine residues of the human metallothionein 1a β-fragment.
- Mass spectrometry confirmed the formation of a stable complex where the Rh2(4+) core is encapsulated by the metallothionein 1a β-fragment.
Conclusions:
- The study elucidates a specific interaction mechanism between a metal-based anticancer agent and a metal-chelating protein.
- The encapsulation of dirhodium(II) tetraacetate by metallothionein 1a β-fragment provides insights into potential drug efficacy modulation.
- Findings are relevant for the design and application of metal-based therapeutics in oncology.
Related Concept Videos
Metal-Ligand Bonds
In these complexes, transition metals form coordinate covalent bonds, a kind of Lewis acid-base interaction in which both of the electrons in the bond are contributed by a donor (Lewis base) to an electron acceptor (Lewis acid). The Lewis acid in...
EDTA: Chemistry and Properties
Complexation Equilibria: The Chelate Effect
Coordination Number and Geometry
EDTA: Auxiliary Complexing Reagents
Properties of Transition Metals

